MediumCardiologyHeart failure with reduced ejection fractionau-amcau-racp
A 72-year-old woman with ischaemic cardiomyopathy (LVEF 30%) is stable on perindopril, frusemide and atorvastatin. Her blood pressure is 115/70 mmHg, heart rate 76 bpm, she is euvolaemic and reports mild exertional dyspnoea, NYHA II. According to Australian heart failure guidelines, which additional medicine provides proven mortality benefit and should be introduced next if tolerated?